Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | GMNN | O75496 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | BLM | P54132 | 3/20 | 0.70 |
| ▸ | CETP | P11597 | 3/20 | 0.70 |
| ▸ | UBE2N | P61088 | 3/20 | 0.70 |
| ▸ | THPO | P40225 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28584076 | 1.00 | CYP2D6 (0.70) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131956 | 1.00 | CYP2D6 (0.70) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL8455217 | 1.00 | CYP2D6 (0.70) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL27938464 | 1.00 | CYP2D6 (0.70) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Hydrochloric Acid SCHEMBL9575893 | 0.98 | CYP2D6 (0.68) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Ammonia Solution, Strong SCHEMBL28467048 | 0.98 | CYP2D6 (0.68) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1132289 | 0.98 | CYP2D6 (0.67) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL6118653 | 0.86 | CYP2D6 (0.76) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL16859677 | 0.86 | CYP2D6 (0.76) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL6118549 | 0.86 | CYP2D6 (0.76) | CYP2D6SPHK1LMNAMAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937100-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-20 | — | — | US | claimed |
| US-20140086863-A1 | Cosmetic Composition | COGNIS IP MANAGEMENT GMBH (DE) | 2014-03-27 | — | — | US | claimed |
| US-8592484-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing | COGNIS IP MANAGEMENT GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| EP-2410977-B1 | COSMETIC COMPOSITION CONTAINING CALCIUM CITRATE AND N-ACYLATED AMINOALCOHOL DERIVATIVE TO PREVENT DRY SKIN AND SIGNS OF CUTANEOUS AGEING | COGNIS IP MAN GMBH (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-8937100-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140086863-A1 | Cosmetic Composition | COGNIS IP MANAGEMENT GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592484-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing | COGNIS IP MANAGEMENT GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2410977-A1 | COSMETIC COMPOSITION CONTAINING CALCIUM CITRATE AND N-ACYLATED AMINOALCOHOL DERIVATIVE TO PREVENT DRY SKIN AND SIGNS OF CUTANEOUS AGEING | Cognis IP Management GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20120016032-A1 | Cosmetic Composition Containing Calcium Citrate And N-Acylated Aminoalcohol Derivative To Prevent Dry Skin And Signs Of Cutaneous Ageing | COGNIS IP MANAGEMENT GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2010108619-A1 | COSMETIC COMPOSITION CONTAINING CALCIUM CITRATE AND N-ACYLATED AMINOALCOHOL DERIVATIVE TO PREVENT DRY SKIN AND SIGNS OF CUTANEOUS AGEING | COGNIS IP MANAGEMENT GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
| EP-2233128-A1 | Cosmetic composition | Cognis IP Management GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086863-A1 | Cosmetic Composition | ASAH2, ASAH1, GLA | CYP2D6 4643/4885SPHK1 1311/4885LMNA 1670/4885 |
| US-20120016032-A1 | Cosmetic Composition Containing Calcium Citrate And N-Acylated Aminoalcohol Derivative To Prevent Dry Skin And Signs Of Cutaneous Ageing | ASAH2, ASAH1, GLA | CYP2D6 4630/4885SPHK1 834/4885LMNA 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.